TY  - JOUR
AU  - Espinosa Bosch, María
AU  - Asensi Diez, Rocío
AU  - García Agudo, Sara
AU  - Clopes Estela, Ana
PY  - 2016
DO  - 10.7399/fh.2016.40.4.10455
SN  - 1130-6343
UR  - http://hdl.handle.net/10668/2509
T2  - Farmacia Hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria
AB  - Nintedanib es un inhibidor de la angiogénesis tumoral que está autorizado por la EMA en combinación con docetaxel para el tratamiento de pacientes adultos con cáncer de pulmón no microcítico (CPNM) localmente avanzado, metastásico o localmente...
AB  - Nintedanib is a triple angiokinase inhibitor that has been approved by the European Agency Medicines (EMA) in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non small cell lung...
LA  - en
PB  - Aula Médica Editores
KW  - Non small cell lung cancer
KW  - Nintedanib
KW  - Cost-effectiveness
KW  - Docetaxel
KW  - Cáncer de pulmón no microcítico
KW  - Coste-efectividad
KW  - Adenocarcinoma
KW  - Adulto
KW  - Carcinoma de pulmón de células no pequeñas
KW  - Análisis costo-beneficio
KW  - Supervivencia sin enfermedad
KW  - Formularios de hospitales
KW  - Humanos
KW  - Incidencia
KW  - Indoles
KW  - Hígado
KW  - Recurrencia local de neoplasia
KW  - Neutropenia
KW  - Calidad de vida
KW  - Taxoides
KW  - Medical Subject Headings::Diseases::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Glandular and Epithelial::Carcinoma::Adenocarcinoma
KW  - Medical Subject Headings::Named Groups::Persons::Age Groups::Adult
KW  - Medical Subject Headings::Diseases::Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms::Bronchial Neoplasms::Carcinoma, Bronchogenic::Carcinoma, Non-Small-Cell Lung
KW  - Medical Subject Headings::Health Care::Health Care Economics and Organizations::Economics::Costs and Cost Analysis::Cost-Benefit Analysis
KW  - Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Survival Analysis::Disease-Free Survival
KW  - Medical Subject Headings::Information Science::Information Science::Communications Media::Publications::Books::Reference Books::Formularies as Topic::Formularies, Hospital
KW  - Medical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans
KW  - Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Vital Statistics::Morbidity::Incidence
KW  - Medical Subject Headings::Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 2-Ring::Indoles
KW  - Medical Subject Headings::Anatomy::Digestive System::Liver
KW  - Medical Subject Headings::Diseases::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Neoplastic Processes::Neoplasm Recurrence, Local
KW  - Medical Subject Headings::Diseases::Hemic and Lymphatic Diseases::Hematologic Diseases::Leukocyte Disorders::Leukopenia::Agranulocytosis::Neutropenia
KW  - Medical Subject Headings::Disciplines and Occupations::Social Sciences::Quality of Life
KW  - Medical Subject Headings::Chemicals and Drugs::Organic Chemicals::Hydrocarbons::Hydrocarbons, Cyclic::Hydrocarbons, Alicyclic::Cycloparaffins::Cyclodecanes::Taxoids
TI  - Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer; GENESIS-SEFH drug evaluation report.
TY  - research article
ER  -